Department of Oncology, University of Oxford, Oxford, UK.
Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, UK.
Theranostics. 2024 Jul 2;14(10):4076-4089. doi: 10.7150/thno.93172. eCollection 2024.
Metastatic tumours in the brain now represent one of the leading causes of death from cancer. Current treatments are largely ineffective owing to the combination of late diagnosis and poor delivery of therapies across the blood-brain barrier (BBB). Conjugating magnetic resonance imaging (MRI) contrast agents with a monoclonal antibody for VCAM-1 (anti-VCAM1) has been shown to enable detection of micrometastases, two to three orders of magnitude smaller in volume than those currently detectable clinically. The aim of this study was to exploit this targeting approach to enable localised and temporary BBB opening at the site of early-stage metastases using functionalised microbubbles and ultrasound. Microbubbles functionalised with anti-VCAM1 were synthesised and shown to bind to VCAM-1-expressing cells . Experiments were then conducted in a unilateral breast cancer brain metastasis mouse model using Gadolinium-DTPA (Gd-DTPA) enhanced MRI to detect BBB opening. Following injection of Gd-DTPA and targeted microbubbles, the whole brain volume was simultaneously exposed to ultrasound (0.5 MHz, 10% duty cycle, 0.7 MPa peak negative pressure, 2 min treatment time). T1-weighted MRI was then performed to identify BBB opening, followed by histological confirmation via immunoglobulin G (IgG) immunohistochemistry. In mice treated with targeted microbubbles and ultrasound, statistically significantly greater extravasation of Gd-DTPA and IgG was observed in the left tumour-bearing hemisphere compared to the right hemisphere 5 min after treatment. No acute adverse effects were observed. There was no investigation of longer term bioeffects owing to the nature of the study. The results demonstrate the feasibility of using targeted microbubbles in combination with low intensity ultrasound to localise opening of the BBB to metastatic sites in the brain. This approach has potential application in the treatment of metastatic tumours whose location cannot be established with conventional imaging methods.
脑转移瘤现在是癌症死亡的主要原因之一。由于晚期诊断和血脑屏障 (BBB) 内治疗药物的输送效率低下,目前的治疗方法在很大程度上效果不佳。将磁共振成像 (MRI) 造影剂与针对 VCAM-1 的单克隆抗体 (抗-VCAM1) 结合使用,已被证明可以检测到体积比目前临床上可检测到的小两到三个数量级的微转移灶。本研究旨在利用这种靶向方法,通过功能化微泡和超声在早期转移部位实现局部和暂时的 BBB 开放。 合成了针对 VCAM-1 的功能化微泡,并证明其可与表达 VCAM-1 的细胞结合。然后在单侧乳腺癌脑转移小鼠模型中进行了实验,使用钆二乙三胺五乙酸 (Gd-DTPA) 增强 MRI 来检测 BBB 开放。注射 Gd-DTPA 和靶向微泡后,整个大脑体积同时暴露于超声 (0.5 MHz、10%占空比、0.7 MPa 峰值负压、2 分钟治疗时间)。然后进行 T1 加权 MRI 以识别 BBB 开放,随后通过免疫球蛋白 G (IgG) 免疫组织化学进行组织学确认。 在接受靶向微泡和超声治疗的小鼠中,与右侧相比,治疗后 5 分钟,左肿瘤负荷半球中 Gd-DTPA 和 IgG 的额外渗透明显更大。未观察到急性不良反应。由于研究的性质,没有对长期生物效应进行研究。 结果表明,使用靶向微泡结合低强度超声将 BBB 局部开放到脑部转移部位是可行的。这种方法有可能应用于那些无法用常规成像方法确定位置的转移性肿瘤的治疗。